We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the top performers last week.
Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-time high, as investors cheered the strong results of its clinical trial testing the efficacy of soquelitinib in patients with moderate to severe eczema.
On Friday alone, the stock jumped to its highest price of $26.95 before giving up all gains to end the session down by 1.65 percent at $25.10 apiece.
In an updated report earlier in the week, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said that its drug candidate successfully demonstrated a 72 percent reduction in the severity of enrolled patients’ eczema in the first phase trial, as compared with the 40 percent reduction for those who took the placebo.
Additionally, the therapy was observed to be even more effective when taken longer, and it was well-tolerated by enrolled patients.
Based on the positive results, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) is planning to initiate a Phase 2 trial in the first quarter of 2026 and enroll 200 patients with moderate-to-severe atopic dermatitis who have failed at least one prior topical or systemic therapy.
The trial is anticipated to enroll four cohorts of 50 patients each, with soquelitinib doses of 200 mg once per day, 200 mg twice per day, and 400 mg once per day, along with a placebo group.
The Phase 2 trial is targeted to run for 12 weeks with a 30-day follow-up period without treatment.
While we acknowledge the potential of CRVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
